Omega-3 AFib Risk Reassessment: Low Doses Safe, High Doses Nuanced
A comprehensive meta-analysis of 114,592 participants clarifies atrial fibrillation (AFib) risk for omega-3s, indicating safety for low-dose formulations (<1,500mg EPA+DHA/day) and nuanced risk for high-dose prescription therapies (>2,000mg/day) in high-risk patients. This re-evaluates previous concerns, providing critical data for product formulation and health professional guidance.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 04 August 2026
A new, expansive meta-analysis challenges prior perceptions regarding omega-3 fatty acids and atrial fibrillation (AFib) risk, offering crucial distinctions for the supplement industry. Published in Circulation: Arrhythmia and Electrophysiology, the study, led by the Fatty Acid Research Institute (FARI), synthesised data from 35 randomised controlled trials (RCTs) involving 114,592 participants. The findings indicate that the risk of AFib is primarily associated with high-dose omega-3 therapies in patients with pre-existing cardiovascular risk, not with typical nutritional doses.
Previous meta-analyses, often limited to eight cardiovascular outcome studies, did not account for a broader range of eligible trials where AFib data, though available, remained unpublished. FARI's approach integrated both published and previously underutilised datasets, including trial registries and studies reporting zero AFib events, to mitigate reporting bias. This expanded evidence base provides a more robust understanding of the relationship between omega-3 supplementation and AFib risk, addressing a long-standing concern that influenced consumer and healthcare professional sentiment.
The study found that low-dose omega-3 supplementation (defined as less than 1,500mg/day of combined EPA and DHA) was not associated with an increased risk of AFib, even in individuals with elevated cardiovascular risk. This is a critical distinction for the dietary supplement market, where most products fall within or below this dosage. Conversely, doses exceeding 2,000mg/day of EPA+DHA did show an increased AFib risk, though the study notes that these high-dose therapies often demonstrate significant benefits in reducing other major cardiovascular events, requiring a careful benefit-risk assessment by clinicians.
Dr. William S. Harris, President of FARI and senior author, highlighted that the relationship is more nuanced than previously suggested, offering reassurance for consumers and clinical guidance for prescribing healthcare providers. Independent experts, such as Dr. Chip Lavie of the Ochsner Heart and Vascular Institute, underscored the strength of evidence from 35 RCTs, reinforcing that daily doses under 1,500mg EPA+DHA do not substantially increase AFib risk.
What this means for United Kingdom
UK manufacturers and brand owners can leverage this meta-analysis to counter prior negative associations between omega-3s and AFib, bolstering consumer confidence and market positioning. Products formulated below 1,500mg/day EPA+DHA can continue to be marketed with greater scientific backing regarding AFib safety, potentially increasing market penetration. Procurement leads should monitor high-dose ingredient specifications (>2,000mg/day) to ensure alignment with medical-grade product requirements and potential regulatory distinctions for prescription vs. supplement categories. Reformulation windows may open for brands to re-emphasise benefits at lower doses without AFib concerns. This evidence provides critical support for discussions with retailers like Boots and Holland & Barrett, who are sensitive to health claims and consumer safety.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.